FY2025 Earnings Estimate for VERA Issued By HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Vera Therapeutics in a research note issued to investors on Wednesday, March 5th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($2.40) per share for the year. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' FY2026 earnings at ($1.79) EPS.

Several other equities research analysts have also recently weighed in on the company. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They set an "overweight" rating and a $70.00 price target on the stock. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective for the company. Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Finally, Guggenheim boosted their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $64.67.

Remove Ads

Vera Therapeutics Stock Performance

Shares of VERA stock traded up $0.56 during trading on Friday, reaching $28.36. 501,306 shares of the company's stock traded hands, compared to its average volume of 881,289. The company has a market capitalization of $1.80 billion, a P/E ratio of -10.87 and a beta of 1.17. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm's 50-day moving average is $34.17 and its 200 day moving average is $39.92.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total transaction of $730,450.00. Following the transaction, the chief executive officer now directly owns 143,603 shares in the company, valued at $5,993,989.22. This trade represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 52,500 shares of company stock valued at $2,305,625. 21.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC raised its holdings in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after acquiring an additional 1,300,410 shares in the last quarter. Vestal Point Capital LP purchased a new position in Vera Therapeutics during the 4th quarter valued at about $45,462,000. Lord Abbett & CO. LLC raised its holdings in shares of Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock valued at $48,788,000 after purchasing an additional 727,656 shares in the last quarter. Federated Hermes Inc. increased its holdings in Vera Therapeutics by 162.2% during the fourth quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock valued at $45,926,000 after buying an additional 671,881 shares during the period. Finally, Integral Health Asset Management LLC increased its holdings in Vera Therapeutics by 130.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock valued at $48,634,000 after buying an additional 650,000 shares during the period. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.